Gyre Therapeutics shareholders approve officer exculpation amendment, elect directors

GYRE THERAPEUTICS, INC.

All three Class III nominees elected: Thomas Eastling (68.9M for), Renate Parry (69.1M), Rodney Nussbaum (69.1M).
Advisory vote on executive compensation approved with 69.1M for, 7,487 against.
Ratification of Grant Thornton as auditor for FY 2024 passed (69.4M for, 7,601 against).
Amendment to certificate of incorporation extending exculpation to certain officers approved (69.0M for).
Certificate of amendment filed with Delaware on June 14, 2024, effective immediately.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.